The ERBB2 receptor is linked to breast adenocarcinoma, the BCR/ABL fusion gene to chronic myelogenous leukemia, and BRAF (V600E) mutations to melanoma, colorectal cancer, and thyroid cancer. Here, BCR is linked to melanoma.